Skip to main content

Treatment Clinical Trials for Acute Lymphoblastic Leukemia (ALL)

Review the acute lymphoblastic leukemia (all) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 150

Genetically Modified Cells (CART19) for the Treatment of Pediatric B cell Acute Lymphoblastic Leukemia
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
2 Step ATG with Preparative Chemotherapy and Methotrexate for the Prevention of Acute GVHD for Patients Undergoing Myeloablative Allogeneic Stem Cell Transplant for Hematopoietic Disorders
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Anti-Thymocyte Globulin added to Tacrolimus and Methotrexate for Reducing Graft Versus Host Disease after Hematopoietic Stem Cell Transplant for Hematologic Cancers
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Standard-of-Care Reduced-Intensity Conditioning with Total Body Irradiation for the Treatment of Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
CART22-65s and huCART19 CAR T Cells for the Treatment of Relapsed or Refractory B-ALL
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Genetically Engineered Cells (huCART19) for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Stem Cell Transplant for Children and Young Adults with Hematologic Malignancies
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Brexucabtagene Autoleucel as Consolidation after Inotuzumab, Blinatumomab and Mini-HCVD or HCVAD for the Treatment of Relapsed/Refractory and Newly Diagnosed B-cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
211^At-BC8-B10 before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Blinatumomab and Asciminib for the Treatment of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
LP-118 in Combination with Ponatinib, Vincristine and Dexamethasone for the Treatment of Relapsed or Refractory T Acute Lymphoblastic Leukemia and T Lymphoblastic Lymphoma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (UCD19 CAR-T Cells) for the Treatment of Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia or B-cell Non-Hodgkin Lymphoma
Status: Active
Location: Children's Hospital Colorado, Aurora, Colorado
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
iC9 CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Relapsed or Refractory T-cell Leukemia or Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Hyper-CVAD in Combination with Venetoclax for the Treatment of Pediatric, Adolescent and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas